Nikolai Kley, Orionis Biosciences CEO

No­var­tis-part­nered Ori­o­n­is se­cures $55M to push cy­tokine pro­gram in­to clin­ic

In sev­en years, a small com­pa­ny has built two pro­grams in im­muno-on­col­o­gy and mol­e­c­u­lar glues and got it­self in­to a part­ner­ship with one of the world’s biggest phar­ma com­pa­nies. Now the transat­lantic biotech has re­filled its cof­fers.

Ori­o­n­is Bio­sciences an­nounced Wednes­day morn­ing that it fin­ished a Se­ries C round and se­cured $55 mil­lion. That in­fu­sion gives Ori­o­n­is flex­i­bil­i­ty to ex­pand its R&D op­er­a­tions, in­crease its pipeline and bring as­sets in­to hu­man tri­als. The biotech plans to in­tro­duce its lead can­di­date, a con­di­tion­al­ly ac­tive cy­tokine ther­a­py, in­to the clin­ic some­time next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.